Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
March 28, 2023 16:45 ET
|
Eloxx Pharmaceuticals
ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial...
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023 16:10 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will...
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed
February 27, 2023 16:05 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first...
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
January 25, 2023 08:00 ET
|
Eloxx Pharmaceuticals
Topline results expected in first half of 2023 Trial sites open in Australia and United Kingdom WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a...
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
December 01, 2022 08:45 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today...
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
November 10, 2022 17:15 ET
|
Eloxx Pharmaceuticals
Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND...
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
November 01, 2022 16:30 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the opening of...
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
September 14, 2022 16:05 ET
|
Eloxx Pharmaceuticals
Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious...
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update
August 15, 2022 08:00 ET
|
Eloxx Pharmaceuticals
Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On track to initiate a proof-of-concept...
Eloxx Pharmaceuticals Announces Changes to Board of Directors
July 05, 2022 08:00 ET
|
Eloxx Pharmaceuticals
Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr....